Newswise — A new Alzheimer’s disease drug will hit the market soon, the first in nearly two decades. But some experts say the evidence for it isn’t terribly strong and worry that it may cost a lot.
Still, the announcement of its approval by the U.S. Food and Drug Administration made headlines nationwide. The attention reflects the toll dementia takes on patients, families and society, and the lack of good treatment options.
Meanwhile, millions of adults could lower the chance that they’ll ever need a drug like that. To do so, they will need to work with their primary care providers and use the power of prevention to keep their brains healthy.
That’s why a national panel of experts including the University of Michigan’s Deborah Levine, M.D., M.P.H., recently published a guide for primary care providers on this topic as an official Scientific Statement from the…